Cargando…

Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus

Bovine parainfluenza type 3 (BPIV3) and bovine respiratory syncytial virus (BRSV) may cause bovine respiratory disease (BRD) in very young calves, and therefore vaccination should induce protection at the youngest age and as quickly as possible. This can be achieved by intranasal vaccination with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuijten, Piet, Cleton, Natalie, van der Loop, Jeroen, Makoschey, Birgit, Pulskens, Wilco, Vertenten, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777984/
https://www.ncbi.nlm.nih.gov/pubmed/35062765
http://dx.doi.org/10.3390/vaccines10010104
_version_ 1784637205917990912
author Nuijten, Piet
Cleton, Natalie
van der Loop, Jeroen
Makoschey, Birgit
Pulskens, Wilco
Vertenten, Geert
author_facet Nuijten, Piet
Cleton, Natalie
van der Loop, Jeroen
Makoschey, Birgit
Pulskens, Wilco
Vertenten, Geert
author_sort Nuijten, Piet
collection PubMed
description Bovine parainfluenza type 3 (BPIV3) and bovine respiratory syncytial virus (BRSV) may cause bovine respiratory disease (BRD) in very young calves, and therefore vaccination should induce protection at the youngest age and as quickly as possible. This can be achieved by intranasal vaccination with a vaccine containing live attenuated BRSV and BPIV3 virus strains. The objective of this study was to measure gene expression levels by means of RT-qPCR of proteins involved in the innate and adaptive immune response in the nasopharyngeal mucosae after administration of the above-mentioned vaccine and after challenge with BPIV3. Gene expression profiles were different between (i) vaccinated, (ii) nonvaccinated-challenged, and (iii) vaccinated-challenged animals. In nonvaccinated-challenged animals, expression of genes involved in development of disease symptoms and pathology were increased, however, this was not the case after vaccination. Moreover, gene expression patterns of vaccinated animals reflected induction of the antiviral and innate immune pathways as well as an initial Th1 (cytotoxic) cellular response. After challenge with BPIV3, the vaccinated animals were protected against nasal shedding of the challenge virus and clinical symptoms, and in parallel the expression levels of the investigated genes had returned to values that were found before vaccination. In conclusion, in comparison to the virulent wild-type field isolates, the two virus strains in the vaccine have lost their capacity to evade the immune response, resulting in the induction of an antiviral state followed by a very early activation of innate immune and antiviral responses as well as induction of specific cellular immune pathways, resulting in protection. The exact changes in the genomes of these vaccine strains leading to attenuation have not been identified. These data represent the real-life situation and can serve as a basis for further detailed research. This is the first report describing the effects on immune gene expression profiles in the nasal mucosae induced by intranasal vaccination with a bivalent, live BRSV-BPI3V vaccine formulation in comparison to wild-type infection with a virulent BPI3V strain.
format Online
Article
Text
id pubmed-8777984
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87779842022-01-22 Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus Nuijten, Piet Cleton, Natalie van der Loop, Jeroen Makoschey, Birgit Pulskens, Wilco Vertenten, Geert Vaccines (Basel) Article Bovine parainfluenza type 3 (BPIV3) and bovine respiratory syncytial virus (BRSV) may cause bovine respiratory disease (BRD) in very young calves, and therefore vaccination should induce protection at the youngest age and as quickly as possible. This can be achieved by intranasal vaccination with a vaccine containing live attenuated BRSV and BPIV3 virus strains. The objective of this study was to measure gene expression levels by means of RT-qPCR of proteins involved in the innate and adaptive immune response in the nasopharyngeal mucosae after administration of the above-mentioned vaccine and after challenge with BPIV3. Gene expression profiles were different between (i) vaccinated, (ii) nonvaccinated-challenged, and (iii) vaccinated-challenged animals. In nonvaccinated-challenged animals, expression of genes involved in development of disease symptoms and pathology were increased, however, this was not the case after vaccination. Moreover, gene expression patterns of vaccinated animals reflected induction of the antiviral and innate immune pathways as well as an initial Th1 (cytotoxic) cellular response. After challenge with BPIV3, the vaccinated animals were protected against nasal shedding of the challenge virus and clinical symptoms, and in parallel the expression levels of the investigated genes had returned to values that were found before vaccination. In conclusion, in comparison to the virulent wild-type field isolates, the two virus strains in the vaccine have lost their capacity to evade the immune response, resulting in the induction of an antiviral state followed by a very early activation of innate immune and antiviral responses as well as induction of specific cellular immune pathways, resulting in protection. The exact changes in the genomes of these vaccine strains leading to attenuation have not been identified. These data represent the real-life situation and can serve as a basis for further detailed research. This is the first report describing the effects on immune gene expression profiles in the nasal mucosae induced by intranasal vaccination with a bivalent, live BRSV-BPI3V vaccine formulation in comparison to wild-type infection with a virulent BPI3V strain. MDPI 2022-01-11 /pmc/articles/PMC8777984/ /pubmed/35062765 http://dx.doi.org/10.3390/vaccines10010104 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nuijten, Piet
Cleton, Natalie
van der Loop, Jeroen
Makoschey, Birgit
Pulskens, Wilco
Vertenten, Geert
Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
title Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
title_full Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
title_fullStr Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
title_full_unstemmed Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
title_short Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
title_sort early activation of the innate immunity and specific cellular immune pathways after vaccination with a live intranasal viral vaccine and challenge with bovine parainfluenza type 3 virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777984/
https://www.ncbi.nlm.nih.gov/pubmed/35062765
http://dx.doi.org/10.3390/vaccines10010104
work_keys_str_mv AT nuijtenpiet earlyactivationoftheinnateimmunityandspecificcellularimmunepathwaysaftervaccinationwithaliveintranasalviralvaccineandchallengewithbovineparainfluenzatype3virus
AT cletonnatalie earlyactivationoftheinnateimmunityandspecificcellularimmunepathwaysaftervaccinationwithaliveintranasalviralvaccineandchallengewithbovineparainfluenzatype3virus
AT vanderloopjeroen earlyactivationoftheinnateimmunityandspecificcellularimmunepathwaysaftervaccinationwithaliveintranasalviralvaccineandchallengewithbovineparainfluenzatype3virus
AT makoscheybirgit earlyactivationoftheinnateimmunityandspecificcellularimmunepathwaysaftervaccinationwithaliveintranasalviralvaccineandchallengewithbovineparainfluenzatype3virus
AT pulskenswilco earlyactivationoftheinnateimmunityandspecificcellularimmunepathwaysaftervaccinationwithaliveintranasalviralvaccineandchallengewithbovineparainfluenzatype3virus
AT vertentengeert earlyactivationoftheinnateimmunityandspecificcellularimmunepathwaysaftervaccinationwithaliveintranasalviralvaccineandchallengewithbovineparainfluenzatype3virus